早期试验后安根的库存量暴跌 表明其减肥药物 MariTide 可能会降低骨头密度 Amgen's stock plunges after early trial data suggests its weight loss drug, MariTide, may decrease bone density.

Amgen的库存量下降7%以上, 此前在实验性减重药物MariTide的早期试验中发现, 12周内骨矿密度可能下降4%。 Amgen's stock dropped over 7% after data from an early-stage trial of its experimental weight loss drug, MariTide, showed a potential 4% decrease in bone mineral density over 12 weeks. 虽然一些分析家认为这是一个安全风险, 但其他人则认为这是一个过度反应, 需要更多数据。 While some analysts see this as a safety risk, others argue it's an overreaction and call for more data. MariTide的目标是每月接受一次,不同于竞争者每周的治疗。 MariTide aims to be taken monthly, unlike weekly treatments from competitors. 华尔街正在等待预期到年底的第二阶段审判结果。 Wall Street awaits phase two trial results expected by year-end.